An Approach to the Patient with a Dry Mouth

Total Page:16

File Type:pdf, Size:1020Kb

An Approach to the Patient with a Dry Mouth MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases. icantly affect quality of life. lated salivary flow seen with mastication. • Patients with salivary Xerostomia also occurs in patients with no Serous saliva is also produced during rest by hypofunction can be treated measurable decrease in saliva production. the submandibular glands. This unstimulated with artificial saliva, Causes of this ‘subjective’ xerostomia include salivary flow is essential for maintenance of moisturising gels, sugar-free burning mouth syndrome (better termed oral and dental health. Mucinous saliva is lozenges or gums and muscarinic drugs Dr Aflaki was a Visiting Academic of the University of Sydney (currently Assistant Professor of Rheumatology, Shiraz (cevimeline, pilocarpine). University of Medical Sciences, Shiraz, Iran) and Dr Erfani was a Basic Physician Trainee Registrar in the Department • Attention to maintaining and of Rheumatology, Westmead Hospital, Sydney (currently a Clinical Research Fellow in the Department of Rheumatology, improving oral health is Royal North Shore Hospital, Sydney). Professor Manolios is Head of the Department of Rheumatology, Westmead important, and treatment of Hospital, Sydney. Dr Schifter is Head of the Department of Oral Medicine, Oral Pathology and Special Needs consequent dental Copyrightcaries is _LayoutDentistry, 1 17/01/12 Westmead 1:43 Hospital, PM Page Sydney; 4 Clinical Associate Professor in the Faculty of Dentistry, the University of essential. Sydney; and a Consultant in Oral Medicine at the Skin and Cancer Foundation Australia, Sydney, NSW. © JACKIE HEDA 30 MedicineToday x APRIL 2014, VOLUME 15, NUMBER 4 Downloaded for personal use only. No other uses permitted without permission. © MedicineToday 2014. produced primarily by minor salivary of the tongue glands. The quality of saliva depends on • a feeling of xerostomia or more 1. CAUSES OF XEROSTOMIA5 the rate of flow. Resting saliva is viscous commonly a sense of an unpleasant and acidic, whereas stimulated saliva is alteration in the texture and quality Psychological and psychiatric hypotonic and alkaline. of the saliva disorders • frequently, dysgeusia. • Anxiety SYMPTOMS OF A DRY MOUTH Best described as an orofacial dysaes- • Depression Several studies have reported discordance thesia, with an element of neuropathic- Burning mouth syndrome between patients’ complaints of xerostomia induced sensory disturbance and associated Hyposalivation and hyposalivation, with a limited associ- psychogenic factors, burning mouth syn- • Medications and other drugs ation observed between perceived dry drome warrants specialist evaluation, for • Rheumatological diseases mouth and decreased salivary flow.2,3 A example by a specialist in oral medicine. − Sjögren’s syndrome South Australian study reported that − Rheumatoid arthritis although dry mouth and hyposalivation Hyposalivation − Systemic lupus erythematosus had similar prevalence estimates (about Drugs − Scleroderma 20%), the two conditions occurred together Hyposalivation is a common side effect of • Immune-mediated conditions in only 6% of participants.4 many medications (see Box 2).6 Most of − Sarcoidosis Symptoms and signs that may accom- these medications affect the neural regu- − Primary biliary cirrhosis pany hyposalivation include: lation of the saliva, which is controlled by • Endocrine disorders • increased thirst and the need to the autonomic nervous system. The sym- − Diabetes mellitus constantly sip or drink water pathetic arm with adrenergic receptors − Diabetes insipidus • difficulty in eating and swallowing inhibits saliva production, and the para- • Radiotherapy (> 50 Gy) encompassing dry foods sympathetic arm with cholinergic (specif- one or more major salivary glands, • difficulty in wearing dentures ically muscarinic) receptors stimulates especially the parotid glands • an increased rate of dental caries saliva production. Many drugs are innately • Metabolic and nutritional disorders • halitosis anticholinergic, thereby limiting or reduc- − Dehydration • a hoarse voice or the inability to ing saliva production. Some drugs and • Infections (viral) speak continuously common beverages such as caffeine and − HIV infection • a constantly sore mouth or throat alcohol also have a diuretic effect, depleting − Hepatitis C • oral candidiasis. the body’s water reserves and so reducing − Cytomegalovirus (and other herpes Other symptoms that suggest sub jective saliva production. infections) xerostomia in the absence of hyposalivation • Renal disease (end-stage) include: Sjögren’s syndrome • Congenital • a burning sensation of the tongue Sjögren’s syndrome (autoimmune exocrin- − Prader–Willi syndrome • a feeling of altered quality and opathy) is a chronic autoimmune disorder − Congenital rubella viscosity of the saliva characterised by lymphocytic infiltration − Lacrimo-auriculo-dento-digital • altered sense of taste (dysgeusia). of all exocrine glands, with destruction of (LADD) syndrome the acini. It is more common in middle- − Complete agenesis of salivary glands CAUSES OF A DRY MOUTH aged women, particularly those of north- Causes of xerostomia are summarised in ern European ancestry. Sjögren’s syndrome Box 1.5 was previously classified as primary or as seen in two-thirds of patients with primary secondary to other autoimmune diseases, Sjögren’s syndrome but is not common Burning mouth syndrome particularly the mixed connective tissue when the syndrome is associated with other A proportion of patients with subjective diseases, rheumatoid arthritis, systemic immune-mediated conditions. Systemic xerostomia have burning mouth syn- lupus erythematosus (SLE) and manifestations are seen in one-third of drome. This poorly understood syndrome scleroderma. patients and include arthralgia, arthritis, presents in the absence of any identifiable The major presenting complaint is Raynaud’s phenomenon and vasculitis. pathology of the oral mucosa or of saliva increasing dryness of the eyes and mouth, Lymphoma (particularly extranodal, production and quantity. It has a typical but the nose, throat, trachea and vagina low-grade marginal zone B cell lymphoma) triad of symptoms:Copyright _Layout 1 17/01/12may 1:43 also PM be Pageaffected. 4 Enlargement of the is a known complication of Sjögren’s • a burning sensation, particularly parotid or other major salivary glands is syndrome.7 MedicineToday x APRIL 2014, VOLUME 15, NUMBER 4 31 Downloaded for personal use only. No other uses permitted without permission. © MedicineToday 2014. APPROACH TO DRY MOUTH CONTINUED Endocrine disorders with a history of radiotherapy or systemic 2. DRUGS THAT COMMONLY The most common endocrine disorders conditions associated with hyposalivation CAUSE SALIVARY HYPOFUNCTION6 that can cause dry mouth include diabetes may indicate progression of the underlying mellitus, hypothyroidism and diabetes disease and the need for more aggressive • Alpha blockers: clonidine, prazosin insipidus. Diabetes mellitus can have two intervention or treatment of the conse- • Angiotensin–converting enzyme major adverse effects on saliva production: quences of salivary hypofunction. inhibitors: captopril, lisinopril diabetes-induced neuropathy of the para- • Anticholinergics: atropine, hyoscine, sympathetic nervous supply results in Physical examination tolterodine reduced saliva and, indirectly, the diuresis Before specifically examining the mouth • Antihistamines: loratadine, fexofenadine, associated with diabetes (also seen with for signs of hyposalivation, assess the diphenhydramine diabetes insipidus) can also impair
Recommended publications
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu Et Al
    US 2003O1086O2A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu et al. (43) Pub. Date: Jun. 12, 2003 (54) TABLETS AND METHODS FOR MODIFIED (22) Filed: Jul. 8, 2002 RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS Related U.S. Application Data (75) Inventors: James Shunnan Chu, Palo Alto, CA (63) Continuation of application No. 09/599,102, filed on (US); Yisong Yang, Sunnyvale, CA May 19, 2000, now Pat. No. 6,419,954. (US); Joseph A. Fix, Half Moon Bay, CA (US) Publication Classification Correspondence Address: (51) Int. Cl. ............................................... A61K 9/20 TOWNSEND AND TOWNSEND AND CREW, (52) U.S. Cl. .............................................................. 424/465 LLP TWO EMBARCADERO CENTER EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) (73) Assignee: Yamanouchi Pharma Technologies, The invention provides a tablet and methods for making the Inc., Palo Alto, CA (US) tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating (21) Appl. No.: 10/191,979 material to modify release of the active agent. Patent Application Publication Jun. 12, 2003 Sheet 1 of 11 US 2003/0108602 A1 (O) N 3(O) 2(O) A/G /A Patent Application Publication Jun. 12, 2003. Sheet 2 of 11 US 2003/0108602 A1 O / O2 OOO OO O Q(SO39 O KC O () i88. OOO OO Okk (ki (k) <k. SJS19O OO <! o O OSS) O O 33 kg) O<< 3k 32 "ooO O & : A/6, 2O Patent Application Publication Jun. 12, 2003 Sheet 3 of 11 US 2003/0108602 A1 Active POWCer (Cevimeline HCI) Formulation Parameters -Pretreatment of Active -Binder: Solid or Solution Binder -% Content of Binder (HPC or PEO/PEG) -Amount of Water Process Parameters -Equipment Selection -Spray Technique Pelletization -Product Temperature (Granulation) -Drying Procedure Process -Milling Technique -High Shear G -Fluid-Bed G In-Process Tests -Yield Active Pellet/Granules -Physical Characteristics -ASSay FIG.
    [Show full text]
  • Parotid Sialolithiasis and Sialadenitis in a 3-Year-Old Child
    Ahmad Tarmizi et al. Egyptian Pediatric Association Gazette (2020) 68:29 Egyptian Pediatric https://doi.org/10.1186/s43054-020-00041-z Association Gazette CASE REPORT Open Access Parotid sialolithiasis and sialadenitis in a 3- year-old child: a case report and review of the literature Nur Eliana Ahmad Tarmizi1, Suhana Abdul Rahim2, Avatar Singh Mohan Singh2, Lina Ling Chooi2, Ong Fei Ming2 and Lum Sai Guan1* Abstract Background: Salivary gland calculi are common in adults but rare in the paediatric population. It accounts for only 3% of all cases of sialolithiasis. Parotid ductal calculus is rare as compared to submandibular ductal calculus. Case presentation: A 3-year-old boy presented with acute painful right parotid swelling with pus discharge from the Stensen duct. Computed tomography revealed calculus obstructing the parotid duct causing proximal ductal dilatation and parotid gland and masseter muscle oedema. The child was treated with conservative measures, and subsequently the swelling and calculus resolved. Conclusions: Small parotid duct calculus in children may be successfully treated with conservative measures which obviate the need for surgery. We discuss the management of parotid sialolithiasis in children and conduct literature search on the similar topic. Keywords: Sialolithiasis, Sialadenitis, Salivary calculi, Parotid gland, Salivary ducts, Paediatrics Background performing computed tomography (CT) of the neck. Sialolithiasis is an obstructive disorder of salivary ductal The unusual presentation, CT findings and its subse- system caused by formation of stones within the salivary quent management were discussed. gland or its excretory duct [1]. The resulting salivary flow obstruction leads to salivary ectasia, gland dilatation Case presentation and ascending infection [2].
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Pilocarpine (Systemic) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Pilocarpine (Systemic) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Salagen Brand Names: Canada JAMP Pilocarpine; M-Pilocarpine; Salagen What is this drug used for? It is used to treat dry mouth. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to pilocarpine or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Asthma, glaucoma, liver disease, or swelling in parts of the eye. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure Pilocarpine (Systemic) 1/6 that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists.
    [Show full text]
  • (Tert- Butoxycarbonyl)Amino](3 361442- 3
    Alternative Name CAS 1. Product Name Use Number 320345- 2. Aclidinium bromide API 99-1 (2S)-[(tert- Butoxycarbonyl)amino](3 361442- 3. Saxagliptin int -hydroxyadamant-1- 00-4 yl)ethanoic acid 1,3- 1,3- 5001-18- 4. Dihydroxyadamantane Adamantanediol 3 1,3-Dimethyladamantane 702-79-4 memantine intermediate 5. 1-Acetylamido-3,5- 19982- 6. Memantine int dimethyladamantane 07-1 1- 7. 880-52-4 Acetylaminoadamantane 1- 4942-47- 8. 1-Adamantaneacetic acid Adamantylacetic 6 acid [2-(1- 6240-11- 9. 1-Adamantaneethanol Adamantylethano 5 l)] 1- 10. 1-Adamantanemethanol Adamantylmetha 770-71-8 nol 1- 1660-04- 1-Adamantyl methyl rimantadine intermediate; 11. Acetyladamantan 4 ketone e 1-Chloro-3,5- 707-36-8 memantine intermediate; 12. dimethyladamantane 1-Hydroxy-3,5- memantine intermediate; 13. 707-37-9 dimethyladamantane 2- 14. 2-Adamantanol Hydroxyadamant 700-57-2 ane 15. 2-Adamantanone 700-58-3 2-Aminoadamantane 10523- 16. hydrochloride 68-9 3-Amino-1-hydroxy- 3-Amino-1- 702-82-9 vildagliptin intermediate; 17. adamantane adamantanol 3- 38584- 18. (Hydroxymethyl)adamant 37-1 -1-ol 19. 3-aminomethyl- 865887- mequitazine intermediate; 20. quinuclidine 14-5 dihydrochloride zacopride intermediate; 6530-09- mezacopride intermediate; 3-Aminoquinuclidine 21. 2 pancopride intermediate; dihydrochloride azasetron intermediate; 3-Carbethoxy-dehydro- quifenadine intermediate; 50790- 22. quinuclidine sequifenadine intermediate; 85-7 hydrochloride quifenadine intermediate; 3- 6238-33- 23. sequifenadine intermediate; Carbethoxyquinuclidine 1 3-hydroxymethyl 79221- mequitazine intermediate; 24. quinuclidine 75-3 hydrochloride 3-Quinuclidine 6238-34- 25. carboxylic acid 2 hydrochloride 1619-34- penehyclidine intermediate; 26. 3-Quinuclidinol 7 clidinium intermediate; cevimeline intermediate; 3-Quinuclidinone 1193-65- 27.
    [Show full text]
  • Drug Class Review Ophthalmic Cholinergic Agonists
    Drug Class Review Ophthalmic Cholinergic Agonists 52:40.20 Miotics Acetylcholine (Miochol-E) Carbachol (Isopto Carbachol; Miostat) Pilocarpine (Isopto Carpine; Pilopine HS) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Glaucoma Therapies ................................................................................................. 5 Table 2. Summary of Agents .................................................................................................. 6 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Glaucoma Clinical Practice Guidelines ................................... 9 Pharmacology ............................................................................................................................... 10 Methods .......................................................................................................................................
    [Show full text]
  • Paediatric Surgery: a Comprehensive Text for Africa
    CHAPTER 39 Salivary Gland Diseases in Children and Adolescents Sunday Olusegun Ajike Kokila Lakhoo Introduction Table 39.1: Classification of salivary gland diseases in children. Salivary glands are found in and around the oral cavity, and they are Nonneoplastic tumours divided into major and minor salivary glands. The major salivary Congenital/developmental glands are the parotid, submandibular, and sublingual glands; the minor Agenesis/aplasia, hypogenesis/hypoplasia salivary glands are located in the lips, buccal mucosa, palate, and throat. Generally, salivary gland diseases are not common in the paediat- Aberrant/ectopic salivary gland ric population. The classification of salivary gland diseases is very Haemangioma complex because it encompasses different entities; however, precise Lympangioma classification and terminology are necessary for accurate diagnosis Inflammatory and infection. and management. As in adults, diseases of the salivary glands may be Acute sialadentis nonneoplastic or neoplastic (tumours) (Table 39.1). The pattern of inci- dence in the paediatric population differs greatly from that in the adult Mumps, cytomegalovirus, Coxasackie A or B or parainfluenza virus) group. Most salivary gland lesions in children are either inflammatory Human immunodeficiency virus (HIV)-associated salivary glands or vascular in origin. Of the developmental salivary gland diseases, Recurrent parotitis in children (RPC) haemangiomas are the most common. In the African paediatric popula- Autoimmune tion, mumps is the most common in the inflammatory/infection group, Sjogren’s syndrome but in the developed world, only sporadic cases of mumps are now reported, and rhabdomyosarcomas are the most common nonodonto- Cysts genic mesenchymal tumours in children. Ranula mucocele (mucous retention cyst) Neoplastic changes in the paediatric population are very rare Salivary gland dysfunction compared to the inflammatory groups.
    [Show full text]
  • Association Between N-Desmethylclozapine and Clozapine-Induced Sialorrhea
    JPET Fast Forward. Published on August 29, 2020 as DOI: 10.1124/jpet.120.000164 This article has not been copyedited and formatted. The final version may differ from this version. 1 Title page Association between N-desmethylclozapine and clozapine-induced sialorrhea: Involvement of increased nocturnal salivary secretion via muscarinic receptors by N- desmethylclozapine Downloaded from Authors and Affiliations: Shuhei Ishikawa, PhD1, 2, a, Masaki Kobayashi, PhD1, 3, *, Naoki Hashimoto, PhD, jpet.aspetjournals.org MD4, Hideaki Mikami, BPharm1, Akihiko Tanimura, PhD5, Katsuya Narumi, PhD1, Ayako Furugen, PhD1, Ichiro Kusumi, PhD, MD4, and Ken Iseki, PhD1 at ASPET Journals on September 23, 2021 1 Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University 2 Department of Pharmacy, Hokkaido University Hospital 3 Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University 4 Department of Psychiatry, Hokkaido University Graduate School of Medicine 5 Department of Pharmacology, School of Dentistry, Health Sciences University of Hokkaido a Present address: Department of Psychiatry, Hokkaido University Hospital JPET Fast Forward. Published on August 29, 2020 as DOI: 10.1124/jpet.120.000164 This article has not been copyedited and formatted. The final version may differ from this version. 2 Running title page Association between N-desmethylclozapine and CIS Corresponding author: Masaki Kobayashi Downloaded from Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12-jo, Nishi-6-chome, jpet.aspetjournals.org Kita-ku, Sapporo 060-0812, Japan. Phone/Fax: +81-11-706-3772/3235. E-mail: [email protected] at ASPET Journals on September 23, 2021 Number of text pages: 25 Number of tables: 1 Number of figures: 6 Number of words in the Abstract: 249 Number of words in the Introduction: 686 Number of words in the Discussion: 1492 JPET Fast Forward.
    [Show full text]
  • Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’
    0270.6474/85/0505-1202$02.00/O The Journal of Neuroscience CopyrIght 0 Society for Neuroscrence Vol. 5, No. 5, pp. 1202-1207 Printed in U.S.A. May 1985 Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’ EDWIN M. MEYER* AND DEBORAH H. OTERO Department of Pharmacology and Therapeutics, University of Florida School of Medicine, Gainesville, Florida 32610 Abstract brain (Gonzales and Crews, 1984). M,-receptors, however, appear pre- and postsynaptically in brain, are regulated by an intrinsic The muscarinic receptors that modulate acetylcholine membrane protein that binds to GTP (g-protein), and may not be release from rat cortical synaptosomes were characterized coupled to changes in phosphatidylinositol turnover. with respect to sensitivity to drugs that act selectively at M, The present studies were designed to determine whether M,- or or Ma receptor subtypes, as well as to changes in ionic Mp-receptors mediate the presynaptic modulation of ACh release. strength and membrane potential. The modulatory receptors These studies involve dose-response curves for the release of appear to be of the M2 type, since they are activated by synaptosomal [3H]ACh in the presence of selected muscarinic ago- carbachol, acetylcholine, methacholine, oxotremorine, and nists and antagonists, as well as treatments that selectively alter MI- bethanechol, but not by pilocarpine, and are blocked by or M,-receptor activity. Our results indicate that the presynaptic atropine, scopolamine, and gallamine (at high concentra- modulation of [3H]ACh release is mediated by MP- but not MI- tions), but not by pirenzepine or dicyclomine.
    [Show full text]
  • Unusual Cancer in Primary Sjögren Syndrome
    Case Report Unusual cancer in primary Sjögren syndrome Wen-Sen Lai MD Feng-Cheng Liu MD PhD Chih-Hung Wang MD PhD Hsin-Chien Chen MD PhD jgren syndrome (SS) is the second most common secondary SS described in the literature to date.3 Here Sautoimmune disease, affecting mainly middle-aged we describe a case of NPC in a patient with primary SS. women. The disease might occur alone (primary SS) or in association with other autoimmune diseases such Case as rheumatoid arthritis (secondary SS). The important A 58-year-old woman with a 2-year history of symp- symptoms of SS, dry mouth (xerostomia) and dry eyes tomatic dry eye and mouth was diagnosed with pri- (keratoconjunctivitis sicca), result from lymphocytic infl- mary SS. Initial general physical examination revealed tration and destruction of the exocrine glands, particu- conjunctival congestion and mucosal atrophy of the larly the salivary and lacrimal glands.1 Patients with tongue with atrophic glossitis. Laboratory serologic SS have an elevated risk of developing malignant neo- analysis showed positive titres for antinuclear anti- plasms, particularly hematologic malignancies, with bodies (1:1280, speckled) and anti–Sjgren syndrome most being non-Hodgkin B-cell lymphoma.2 Other can- antigens A and B (>240 U/mL and 172 U/mL, respec- cers, such as oral cancer, breast cancer, and thymoma, tively). Screening for SS showed decreased salivary might also occur in patients with SS. However, the coex- gland function and globular sialectasis on parotid istence of SS with nasopharyngeal carcinoma (NPC) sialography. Results of a Schirmer test during the oph- has rarely been reported, with only one case involving thalmologic examination were positive for dry eyes, and a labial salivary gland biopsy (Figure 1) revealed focal chronic sialadenitis characterized by intense lymphocytic inflammatory infiltrate (focus score >2; EDITOR’S KEY POINTS >100 lymphocytes/4 mm2 of glandular tissue).
    [Show full text]